Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer (Q38843828)

6 September 2017

title

Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer (English)

1 reference

6 September 2017

author name string

Mohammed Kashif Siddiqui

1

1 reference

6 September 2017

Jerzy Tyczynski

2

1 reference

6 September 2017

Ankit Pahwa

3

1 reference

6 September 2017

Ancilla W Fernandes

4

1 reference

6 September 2017

language of work or name

English

0 references

publication date

7 April 2017

1 reference

6 September 2017

1 reference

6 September 2017

volume

146

1 reference

6 September 2017

issue

1

1 reference

6 September 2017

page(s)

44-51

1 reference

6 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Surrogate endpoint analysis: an exercise in extrapolation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Does the Prentice criterion validate surrogate endpoints?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Individual- and trial-level surrogacy in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

Surrogate measures and consistent surrogates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2017.03.515

10.1016/J.YGYNO.2017.03.515

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference